Table 1. Baseline recipient, donor, and transplant characteristics.
| Characteristics | T1DM (n=18) | T2DM (n=45) | P |
|---|---|---|---|
| Age, years | 35.72±6.70 | 49.79±8.53 | 0 |
| BMI, kg/m2 | 23.83±3.15 | 25.45±3.09 | 0.068 |
| Duration of diabetes, years | 156.11±92.56 | 245.62±75.72 | 0 |
| Hypertension | 0.913 | ||
| Grade II | 3 | 7 | |
| Grade III | 15 | 38 | |
| Coronary artery disease | 0.786 | ||
| Yes | 2 | 4 | |
| No | 16 | 41 | |
| Cerebrovascular disease | 0.495 | ||
| Yes | 1 | 1 | |
| No | 17 | 44 | |
| PRA | 0.852 | ||
| Positive | 1 | 2 | |
| Negative | 17 | 43 | |
| Fasting blood glucose | 5.79±0.59 | 5.67±0.61 | 0.477 |
| Degree of HLA mismatch | 0.864 | ||
| 2 | 2 | 3 | |
| 3 | 13 | 32 | |
| 4 | 1 | 5 | |
| 5 | 2 | 5 | |
| Dialysis modality | 0.042 | ||
| None | 1 | 8 | |
| Peritoneal dialysis | 2 | 0 | |
| Hemodialysis | 15 | 37 | |
| Induction | 0.501 | ||
| ATG | 4 | 5 | |
| Thymoglobulin + basiliximab | 13 | 38 | |
| Multiple | 1 | 2 | |
| Calcineurin inhibitor | 0.852 | ||
| Cyclosporine A | 1 | 2 | |
| Tacrolimus | 17 | 43 | |
| Donor age | 30.55±7.30 | 29.13±10.79 | 0.610 |
| Hospital day | 28.78±15.81 | 27.78±12.16 | 0.788 |
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; BMI, body mass index; PRA, panel-reactive antibody; HLA, human leukocyte antigen; ATG, antithymocyte globulin.